Dr. Yinong Liu, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1121 Kinneys Ln, Portsmouth, OH 45662 Phone: 740-356-7490 Fax: 740-356-7488 |
Tsuyoshi Inoshita, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 916 11th St, Portsmouth, OH 45662 Phone: 740-353-4884 Fax: 740-353-8798 |
Hassaan Jafri, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 916 11th St, Portsmouth, OH 45662 Phone: 740-353-4884 Fax: 740-353-8798 |
Dr. Nanda K. Methuku, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1121 Kinneys Ln, Portsmouth, OH 45662 Phone: 740-356-7490 Fax: 740-356-7488 |
News Archive
For decades, researchers have debated whether Alzheimer's disease starts independently in vulnerable brain regions at different times, or if it begins in one region and then spreads to neuroanatomically connected areas. A new study by Columbia University Medical Center (CUMC) researchers strongly supports the latter, demonstrating that abnormal tau protein, a key feature of the neurofibrillary tangles seen in the brains of those with Alzheimer's, propagates along linked brain circuits, "jumping" from neuron to neuron.
Young children in developing countries are infected at an early age with the bacterium Helicobacter pylori, which can cause peptic ulcers and stomach cancer. New findings show that childrensĀ“ immune responses help in fighting the bacteria. In addition, breastfeeding and better hygiene appear to protect against infection. The results provide hope for a vaccine, according to research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.
The bacterium B. cereus had so far been considered to be exclusively endospore-forming. In response to harsh conditions, the bacteria form protective endospores enabling them to remain dormant for extended periods. When conditions are more favourable, the endospores reactivate to become fully functioning bacteria.
PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.
Greatbatch, Inc., today announced results for its first quarter ended March 29, 2013 highlighted by a 19% increase in adjusted diluted EPS despite negative 4% constant currency organic revenue growth.
› Verified 1 days ago